Insider Transactions in Q3 2021 at Generation Bio Co. (GBIO)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 29
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30
-4.7%
|
$720
$24.59 P/Share
|
|
Sep 29
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
16,556
-100.0%
|
$397,344
$24.59 P/Share
|
|
Sep 29
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
16,586
-52.35%
|
$398,064
$24.59 P/Share
|
|
Sep 28
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
24
-3.63%
|
$600
$25.24 P/Share
|
|
Sep 28
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,089
-44.15%
|
$327,225
$25.24 P/Share
|
|
Sep 28
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
13,113
-23.89%
|
$327,825
$25.24 P/Share
|
|
Sep 27
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
95
-12.55%
|
$2,375
$25.7 P/Share
|
|
Sep 27
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
51,294
-63.37%
|
$1,282,350
$25.7 P/Share
|
|
Sep 27
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
51,389
-37.96%
|
$1,284,725
$25.7 P/Share
|
|
Sep 24
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
54
-6.66%
|
$1,350
$25.84 P/Share
|
|
Sep 24
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
28,862
-26.29%
|
$721,550
$25.84 P/Share
|
|
Sep 24
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
28,916
-16.47%
|
$722,900
$25.84 P/Share
|
|
Sep 23
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
140
-14.72%
|
$3,640
$26.13 P/Share
|
|
Sep 23
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
75,325
-20.34%
|
$1,958,450
$26.34 P/Share
|
|
Sep 23
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
75,465
-18.47%
|
$1,962,090
$26.27 P/Share
|
|
Sep 22
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
57
-5.65%
|
$1,425
$25.89 P/Share
|
|
Sep 22
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,560
-14.17%
|
$764,000
$25.89 P/Share
|
|
Sep 22
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
30,617
-9.91%
|
$765,425
$25.89 P/Share
|
|
Sep 17
2021
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
100,000
-7.89%
|
-
|
|
Sep 17
2021
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,000,000
-12.33%
|
-
|
|
Sep 14
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
4,500
-2.22%
|
$126,000
$28.07 P/Share
|
|
Sep 14
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+2.17%
|
$18,000
$4.59 P/Share
|
|
Sep 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
3,000
-0.75%
|
$78,000
$26.22 P/Share
|
|
Sep 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+1.47%
|
$12,000
$4.59 P/Share
|
|
Aug 23
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$37,500
$25.04 P/Share
|
|
Aug 23
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$6,000
$4.59 P/Share
|
|
Aug 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.25%
|
$34,500
$23.24 P/Share
|
|
Aug 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$6,000
$4.59 P/Share
|
|
Jul 12
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
3,000
-0.75%
|
$72,000
$24.96 P/Share
|
|
Jul 12
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+1.47%
|
$12,000
$4.59 P/Share
|
|
Jul 08
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,518
-0.53%
|
$87,950
$25.19 P/Share
|
|
Jul 08
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,518
+1.05%
|
$17,590
$5.16 P/Share
|